Update on Locoregional Therapies for Cholangiocellular Carcinoma

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2023 May 16

PMID 37190295

Authors

Janna Morawitz

Nils-Martin Bruckmann

Kai Jannusch

Julian Kirchner

Gerald Antoch

Sven Loosen

Tom Luedde

Christoph Roderburg

Peter Minko

Affiliations

Soon will be listed here.

Abstract

Locoregional therapy options for CCA are used, in particular, for non-resectable tumors and aim to reduce tumor viability or delay tumor growth and ultimately prolong overall survival. In addition to local ablative procedures such as radiofrequency- or microwave-ablation, transarterial procedures such as transarterial embolization (TAE), transarterial chemoembolization (TACE), or selective internal radiotherapy (SIRT) play a major role. In particular, in combination with advances in molecular medicine and immunotherapy, there has been a further development in the therapy of primary malignant liver tumors in recent years. In this review, we analyze data from recent studies and examine the implications for therapy of CCA, particularly with regard to the combination of locoregional therapies with modern systemic therapies.

Citing Articles

The Efficacy and Safety of Hepatic Artery Infusion Chemotherapy Combined with Lenvatinib and Programmed Death (PD)-1 Inhibitors for Unresectable Intrahepatic Cholangiocarcinoma: A Retrospective Study.

Cai Y, Wen W, Xia Y, Wan R Curr Oncol. 2025; 32(2).

PMID: 39996887 PMC: 11854701. DOI: 10.3390/curroncol32020087.

References

Mondaca S, Yarmohammadi H, Kemeny N . Regional Chemotherapy for Biliary Tract Tumors and Hepatocellular Carcinoma. Surg Oncol Clin N Am. 2019; 28(4):717-729. PMC: 8240360. DOI: 10.1016/j.soc.2019.06.008. View

Cantore M, Mambrini A, Fiorentini G, Rabbi C, Zamagni D, Caudana R . Phase II study of hepatic intraarterial epirubicin and cisplatin, with systemic 5-fluorouracil in patients with unresectable biliary tract tumors. Cancer. 2005; 103(7):1402-7. DOI: 10.1002/cncr.20964. View

Treska V, Bruha J, Skalicky T, Liska V, Fichtl J, Mirka H . Radiofrequency ablation of colorectal liver metastases. Rozhl Chir. 2019; 98(10):399-403. View

Patel T . Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology. 2001; 33(6):1353-7. DOI: 10.1053/jhep.2001.25087. View

Slabaugh T, Ogan K . Renal tumor radiofrequency ablation. Minerva Urol Nefrol. 2005; 57(4):261-9. View

Konstantinidis I, Groot Koerkamp B, Do R, Gonen M, Fong Y, Allen P . Unresectable intrahepatic cholangiocarcinoma: Systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone. Cancer. 2015; 122(5):758-65. PMC: 4764409. DOI: 10.1002/cncr.29824. View

Wu L, Tsilimigras D, Paredes A, Mehta R, Hyer J, Merath K . Trends in the Incidence, Treatment and Outcomes of Patients with Intrahepatic Cholangiocarcinoma in the USA: Facility Type is Associated with Margin Status, Use of Lymphadenectomy and Overall Survival. World J Surg. 2019; 43(7):1777-1787. DOI: 10.1007/s00268-019-04966-4. View

ENSMINGER W . Regional chemotherapy. Semin Oncol. 1993; 20(1):3-11. View

Kudo M, Ueshima K, Ikeda M, Torimura T, Tanabe N, Aikata H . Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. Gut. 2019; 69(8):1492-1501. PMC: 7398460. DOI: 10.1136/gutjnl-2019-318934. View

10.

Kloeckner R, Ruckes C, Kronfeld K, Worns M, Weinmann A, Galle P . Selective internal radiotherapy (SIRT) versus transarterial chemoembolization (TACE) for the treatment of intrahepatic cholangiocellular carcinoma (CCC): study protocol for a randomized controlled trial. Trials. 2014; 15:311. PMC: 4132905. DOI: 10.1186/1745-6215-15-311. View

11.

Cercek A, Boerner T, Tan B, Chou J, Gonen M, Boucher T . Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial. JAMA Oncol. 2019; 6(1):60-67. PMC: 6824231. DOI: 10.1001/jamaoncol.2019.3718. View

12.

Haidu M, Dobrozemsky G, Schullian P, Widmann G, Klaus A, Weiss H . Stereotactic radiofrequency ablation of unresectable intrahepatic cholangiocarcinomas: a retrospective study. Cardiovasc Intervent Radiol. 2011; 35(5):1074-82. DOI: 10.1007/s00270-011-0288-6. View

13.

Ray Jr C, Edwards A, Smith M, Leong S, Kondo K, Gipson M . Metaanalysis of survival, complications, and imaging response following chemotherapy-based transarterial therapy in patients with unresectable intrahepatic cholangiocarcinoma. J Vasc Interv Radiol. 2013; 24(8):1218-26. DOI: 10.1016/j.jvir.2013.03.019. View

14.

Kim Y, Lee W, Rhim H, Lim H, Choi D, Lee J . The minimal ablative margin of radiofrequency ablation of hepatocellular carcinoma (> 2 and < 5 cm) needed to prevent local tumor progression: 3D quantitative assessment using CT image fusion. AJR Am J Roentgenol. 2010; 195(3):758-65. DOI: 10.2214/AJR.09.2954. View

15.

Han K, Ko H, Kim K, Won H, Shin Y, Kim P . Radiofrequency ablation in the treatment of unresectable intrahepatic cholangiocarcinoma: systematic review and meta-analysis. J Vasc Interv Radiol. 2015; 26(7):943-8. DOI: 10.1016/j.jvir.2015.02.024. View

16.

Dewaraja Y, Devasia T, Kaza R, Mikell J, Owen D, Roberson P . Prediction of Tumor Control in Y Radioembolization by Logit Models with PET/CT-Based Dose Metrics. J Nucl Med. 2019; 61(1):104-111. PMC: 6954459. DOI: 10.2967/jnumed.119.226472. View

17.

Cremonesi M, Chiesa C, Strigari L, Ferrari M, Botta F, Guerriero F . Radioembolization of hepatic lesions from a radiobiology and dosimetric perspective. Front Oncol. 2014; 4:210. PMC: 4137387. DOI: 10.3389/fonc.2014.00210. View

18.

Tanaka N, Yamakado K, Nakatsuka A, Fujii A, Matsumura K, Takeda K . Arterial chemoinfusion therapy through an implanted port system for patients with unresectable intrahepatic cholangiocarcinoma--initial experience. Eur J Radiol. 2001; 41(1):42-8. DOI: 10.1016/s0720-048x(01)00414-4. View

19.

Chen K, Chen G, Wang H, Li H, Xiao J, Duan X . Increased survival in hepatocellular carcinoma with iodine-125 implantation plus radiofrequency ablation: a prospective randomized controlled trial. J Hepatol. 2014; 61(6):1304-11. DOI: 10.1016/j.jhep.2014.07.026. View

20.

Mafeld S, Wong J, Kibriya N, Stenberg B, Manas D, Bassett P . Percutaneous Irreversible Electroporation (IRE) of Hepatic Malignancy: A Bi-institutional Analysis of Safety and Outcomes. Cardiovasc Intervent Radiol. 2018; 42(4):577-583. PMC: 6394503. DOI: 10.1007/s00270-018-2120-z. View